Marzese Diego M, Hoon Dave Sb
Department of Molecular Oncology, Saint John's Health Center, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA.
Expert Rev Mol Diagn. 2015 May;15(5):647-64. doi: 10.1586/14737159.2015.1027194. Epub 2015 Mar 22.
DNA methylation is an epigenetic mechanism that plays a key role in regulating gene expression and other functions. Although this modification is seen in different sequence contexts, the most frequently detected DNA methylation in mammals involves cytosine-guanine dinucleotides. Pathological alterations in DNA methylation patterns are described in a variety of human diseases, including cancer. Unlike genetic changes, DNA methylation is heavily influenced by subtle modifications in the cellular microenvironment. In all cancers, aberrant DNA methylation is involved in the alteration of a large number of oncological pathways with relevant theranostic utility. Several technologies for DNA methylation mapping have been developed recently and successfully applied in cancer studies. The scope of these technologies varies from assessing a single cytosine-guanine locus to genome-wide distribution of DNA methylation. Here, we review the strengths and weaknesses of these approaches in the context of clinical utility for the molecular diagnosis of human cancers.
DNA甲基化是一种表观遗传机制,在调节基因表达和其他功能中起关键作用。尽管这种修饰存在于不同的序列背景中,但在哺乳动物中最常检测到的DNA甲基化涉及胞嘧啶-鸟嘌呤二核苷酸。DNA甲基化模式的病理改变在包括癌症在内的多种人类疾病中都有描述。与基因变化不同,DNA甲基化受到细胞微环境中细微修饰的严重影响。在所有癌症中,异常的DNA甲基化都参与了大量具有相关诊疗效用的肿瘤学通路的改变。最近已经开发了几种用于DNA甲基化图谱分析的技术,并成功应用于癌症研究。这些技术的范围从评估单个胞嘧啶-鸟嘌呤位点到DNA甲基化的全基因组分布。在这里,我们在人类癌症分子诊断的临床效用背景下综述这些方法的优缺点。